Adoptive CD8+ T cell therapy refers to an immunotherapy approach in which tumor-infiltrating lymphocytes (TILs) isolated from tumor specimen are activated and expanded in vitro to large quantities, using anti-CD3/CD28 antibodies and IL-2, and then transferred back to the cancer patients [56]. The gene discussed is CD8A; the disease is neoplasm.